GSK spins out corporate VC fund focused on bioelectronic technews2025-12-12T14:11:50+00:00December 12th, 2025|Endpoints News|
Weight loss biotech Prolynx gets $70M, snags Amgen’s obesity commercial leader as CEOnews2025-12-11T12:00:12+00:00December 11th, 2025|Endpoints News|
PsiThera gets $47.5M for oral I&I drugs after spinning out from Roivantnews2025-12-10T12:00:41+00:00December 10th, 2025|Endpoints News|
BlossomHill gets another $84M for macrocyclic approach to EGFRnews2025-12-10T11:30:14+00:00December 10th, 2025|Endpoints News|
SanegeneBio raises $110M in follow-up to metabolic deal with Lillynews2025-12-09T16:43:39+00:00December 9th, 2025|Endpoints News|
EpilepsyGTx gets $33M to test epilepsy gene therapy in Phase 1/2anews2025-12-09T16:00:08+00:00December 9th, 2025|Endpoints News|
Kallyope heads to Phase 3 with migraine drug after mid-stage successnews2025-12-08T11:30:40+00:00December 8th, 2025|Endpoints News|
OTR Therapeutics gets $100M from Pfizer Ventures, others to build asset portfolionews2025-12-05T15:27:01+00:00December 5th, 2025|Endpoints News|
ARCH, Lilly Asia Ventures return to back US-China startup SciNeuronews2025-12-04T12:00:42+00:00December 4th, 2025|Endpoints News|
Clinical trials tech startup Paradigm raises $78M, acquires part of Roche’s Flatironnews2025-12-04T11:00:00+00:00December 4th, 2025|Endpoints News|
